A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
CTRC Inpatient, University of Colorado Hospital
|
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
University of Colorado Hospital
|
ANHL1931- A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Childrens Hospital Colorado
|
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients with Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
Highlands Ranch Hospital, Outpatient CTRC, University of Colorado Hospital
|
Do decreased dietary fat and increased fiber reduce recurrence of Clostridioides difficile infection in oncology patients?
Childrens Hospital Colorado, University of Colorado Hospital
|
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
University of Colorado Hospital
|
PHASE 1/2 DOSE ESCALATION AND PRELIMINARY EFFICACY OF CD19 DIRECTED CAR T CELLS GENERATED USING THE MILTENYI CLINIMACS PRODIGY SYSTEM (UCD19 CART) IN PEDIATRIC PATIENTS WITH REPLASED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL)
Childrens Hospital Colorado
|
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies
CTRC Inpatient, University of Colorado Hospital
|
Total Joint Arthroplasty in a Pediatric Population
Childrens Hospital Colorado
Involves two surveys for approximately 10 mintues...
|
APEC1621-MASTER, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Childrens Hospital Colorado
|
051/02 A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Childrens Hospital Colorado
|
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Childrens Hospital Colorado
|
Blood Disorder Symptomatology Outcomes Network Patient Reported Outcomes (BISON-PRO) Quality of Life Study
Cherry Creek Medical Center, University of Colorado Hospital
The BISON-PRO Quality of Life Study is a research study to measure symptoms and quality of life using online surveys in patients with blood disorders....
|
A PILOT STUDY OF PROSPECTIVE PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ADULT AND PEDIATRIC PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL)
University of Colorado Hospital
|
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or r...
|
A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants with Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination with Tyrosine Kinase Inhibitors
New York University, Outpatient CTRC, University of Colorado Hospital, University of Michigan, University of Michigan Comprehensive Cancer Center
Although non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK), c-ros oncogene 1(ROS1), and ret proto-oncogene (RET) gene fusions initially respond well to tyrosine kinase inhibitor (TKI) therapies, acquired resistance is inevitable. In many of these cases, incr...
|
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
PEPN2011: A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Childrens Hospital Colorado
For Patients on Part A: D with a solid tumor, lymphoma or desmoid tumor that has either come back or does not respond to therapy, or a desmoid tumor that cannot be removed safely by surgery.
For Patients on Part B: Diagnosed with a relapsed or refractory Ewing sarcoma, desmoid tumor, os...
|
